CERT
Certara, Inc.

Certara, Inc.CERT

Healthcare · Health Information Services
12.05USD
-1.07%
Nov 09, 2026
CERT overview ready
Regulatory-Grade Biosimulation Software and Services for Biopharma
Certara is a specialized software-and-scientific-services provider enabling biopharma customers and regulators to use biosimulation and model-informed evidence across drug discovery, preclinical work, clinical development, and submissions.
Theme not measured
Drug-Discovery Simulation Software has no leadership state this session.
An early price trend
Longer-term context reads early recovery, with a near-term setup of daily advance.
Fair valuation
The price broadly reflects how much growth and cash flow it delivers per turn of revenue multiple, with upside and risk reasonably balanced.
Solid fundamentals
Free cash flow yield is strong.
Primary risk
Dependence on pharmaceutical R&D budgets and regulatory environment.
Market Nov 6Filing Sep 30Price action Nov 8Research Oct 15

Conviction Level

Theme Momentum has no canonical measurement for this company — a research-profile dimension, not an input to this score.

PriceAction8.3BusinessPerformance7.0BusinessQuality5.2Valuation3.6ThemeMomentum—Improving — Revenue growth has accelerated, rising from +0.9% to +4.4% year over year. One recent quarter could not be confirmed and is not part of this read. Diluted EPS moved to $0.04 from $0.01; the prior-year base is too small for a meaningful percentage. — From filed financial statements. Describes the recent trajectory of the business, not the stock. 20 of the 100 Conviction points.

Conviction uses Price Action, Business Performance, Business Quality, Valuation. Theme Momentum is research context, not an input.

Theme momentumPrimary theme · group context, not entry timing
Drug-Discovery Simulation Software — Drug-Discovery Simulation Software has only one or two priced members — no leadership state
Its economic family, Biotechnology, reads Improving (+5.9pp vs SPY) — the family’s reading, not this theme’s.
Price
Loading price history…

Price Action

An early price trend
Longer-term context reads early recovery, with a near-term setup of daily advance.
EntryEarly recovery

The structure is repairing early: weekly fast averages are being reclaimed and the daily chart is recovering constructively — an early-recovery entry profile.

Key Financials

Market Cap
$1.8B
Avg Volume (60D)
2.7M
60 sessions
Revenue Growth YoY
+8.7%
FY2025 vs FY2024
Gross Margin
+49.9%
Trailing twelve months
Operating Margin
+1.3%
Trailing twelve months
Free Cash Flow Yield
+4.3%
Distance from 200DMA
+64.8%
P/E
N/M
EV / EBITDA
23.2x
EV / Sales
4.5x
Market metrics as of Nov 6, 2026
Financial results for the period ended Sep 30, 2026
Filed balance-sheet data as of Sep 30, 2026

Business Performance

Improving

Revenue growth has accelerated, rising from +0.9% to +4.4% year over year. One recent quarter could not be confirmed and is not part of this read. Diluted EPS moved to $0.04 from $0.01; the prior-year base is too small for a meaningful percentage.

Latest reported: Q3 FY2026, ended Sep 30
Revenue growthAccelerating
+4.4%
$94.9M in Q3 FY2026 · YoY
YoY growth, last 4 quarters
  1. n/a
  2. +0.9%
  3. +1.0%
  4. +4.4%
Earnings growthGrowing
$0.04
Diluted EPS $0.04 vs $0.01 a year earlier · GAAP
Too few comparable EPS quarters: a loss or a turn to profit has no meaningful percentage.
Operating marginStable
2.5%
+3.1 pp YoY

Business Quality

5.2 / 10

How well the business earns on its assets, converts earnings to cash and funds itself — read from its SEC filings.

Fundamentals & Valuation

Two of the three valuation perspectives say fair; own history is the dissenting view.
Certara, Inc. has a Fair valuation stance because the price broadly reflects how much growth and cash flow it delivers per turn of revenue multiple, with upside and risk reasonably balanced.

Company Research

Thesis
Certara is a specialized software-and-scientific-services provider enabling biopharma customers and regulators to use biosimulation and model-informed evidence across drug discovery, preclinical work, clinical development, and submissions.
Opportunity
Moderate opportunity
Pharmaceutical and biotechnology investment in mechanistic modeling, simulation, pharmacometrics, and validated AI-enabled evidence generation to improve development decisions, trial design, dose selection, and regulatory submissions.
Key risk
Dependence on pharmaceutical R&D budgets and regulatory environment.

Economic classification

Loading the economic classification…

Business & Markets

Healthcare · Health Information Services
What they do

Certara provides technology-driven software and scientific services that enable biosimulation and model-informed drug development across discovery, preclinical, clinical research, regulatory submissions, and market access globally.

How it earns

Revenue is generated primarily through subscription and project-based contracts for software licenses and scientific consulting services.

Products & services
Simcyp simulator
Model-informed drug development solutions
Biosimulation services
Customers & end markets
Pharmaceutical companies
Biotechnology firms
Regulatory agencies
Market position

Niche leader specializing in regulatory-grade biosimulation and model-informed drug development software and services.

Demand drivers
Medium cyclicality

Demand is linked to pharmaceutical R&D spending which can fluctuate with industry cycles and regulatory environments.